Baron & Budd, P.C. Company Profile

Background

Overview

Baron & Budd, P.C. is a prominent plaintiffs' law firm headquartered in Dallas, Texas. Established in 1977, the firm has built a reputation for its dedication to representing individuals and public entities in complex litigation cases across the United States. With over four decades of experience, Baron & Budd has become one of the largest and most accomplished plaintiffs' law firms in the country.

Mission and Vision

The firm's mission, encapsulated in their motto "Protecting What’s Right," reflects their commitment to safeguarding the rights and interests of their clients. Their vision is to remain at the forefront of litigation, handling complex cases that have a significant impact on society.

Primary Area of Focus

Baron & Budd specializes in various areas of plaintiffs' litigation, including:

Asbestos and Mesothelioma Litigation: Pioneering mesothelioma lawsuits, representing some of the first mesothelioma victims over 45 years ago.

Environmental Contamination: Addressing issues such as water contamination and environmental pollution.

Pharmaceutical and Medical Device Litigation: Handling cases involving dangerous and defective medical products.

Mass Torts and Class Actions: Representing large groups of individuals affected by corporate wrongdoing.

Industry Significance

Baron & Budd has achieved substantial national acclaim for its work on cutting-edge litigation, trying hundreds of cases to verdict and settling tens of thousands of cases in areas such as dangerous pharmaceuticals, defective medical devices, asbestos and mesothelioma, wildfires, environmental contamination, fraudulent banking practices, e-cigarettes, motor vehicles, federal whistleblower cases, and other consumer fraud issues.

Key Strategic Focus

Core Objectives

The firm's primary objectives include:

Client Advocacy: Providing dedicated representation to individuals and public entities affected by corporate negligence.

Litigation Excellence: Achieving favorable outcomes in complex and high-profile cases.

Public Service: Contributing to societal well-being through impactful legal actions.

Specific Areas of Specialization

Baron & Budd focuses on:

Asbestos and Mesothelioma Cases: Representing victims of asbestos exposure.

Environmental Litigation: Addressing contamination issues affecting communities.

Pharmaceutical and Medical Device Litigation: Handling cases involving harmful medical products.

Mass Torts and Class Actions: Representing large groups of individuals in complex legal actions.

Key Technologies Utilized

While specific technological platforms are not detailed, the firm employs advanced legal research tools, case management software, and data analytics to support their litigation efforts.

Primary Markets or Conditions Targeted

Baron & Budd primarily targets:

Individuals: Especially those affected by asbestos exposure, environmental contamination, and defective medical products.

Public Entities: Including cities, counties, and municipalities involved in mass torts and class actions.

Financials and Funding

As a privately held law firm, Baron & Budd does not publicly disclose detailed financial information or funding history.

Pipeline Development

The firm is actively involved in ongoing litigation and settlement negotiations across various practice areas, including:

Opioid Litigation: Serving on the Plaintiffs' Executive Committee in the National Prescription Opiate Litigation, MDL 2804.

Environmental Contamination: Securing significant settlements in water contamination cases, such as the $12.5 billion nationwide class settlement with 3M for PFAS contamination.

Pharmaceutical and Medical Device Cases: Representing clients in litigation involving dangerous and defective medical products.

Technological Platform and Innovation

Proprietary Technologies

While specific proprietary technologies are not detailed, the firm utilizes advanced legal research tools, case management software, and data analytics to support their litigation efforts.

Significant Scientific Methods

The firm employs scientific methodologies relevant to their cases, including:

Medical Research: Utilizing expert testimony and scientific studies in asbestos and mesothelioma cases.

Environmental Analysis: Conducting environmental assessments in contamination cases.

Product Testing: Engaging in testing and analysis in pharmaceutical and medical device litigation.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, the firm likely employs AI tools for legal research, document review, and case prediction to enhance efficiency and effectiveness.

Leadership Team

Key Executives

Russell W. Budd: President and Managing Shareholder. With over 45 years of experience, Budd has been instrumental in leading high-impact litigation against corporate wrongdoing. He has secured landmark settlements in asbestos, banking, pharmaceuticals, and national opioid cases, helping recover tens of billions for victims.

Steve Baron: Shareholder and head of the mesothelioma litigation section. Baron has been representing mesothelioma sufferers for more than 30 years, achieving successful verdicts and settlements, including a $55 million mesothelioma verdict in El Paso, Texas.

Scott Summy: Shareholder and leader of the Environmental Litigation Group. Summy has been recognized for his significant contributions to environmental litigation, including securing a record $12.5 billion nationwide class settlement with 3M for PFAS contamination.

Roland K. Tellis: Shareholder and Chair of the Class Action practice. Tellis has served as co-lead counsel in high-profile class action lawsuits, including a $445.5 million class settlement with Hino Motors, Ltd.

John Fiske: Shareholder representing public entities. Fiske has resolved approximately $2.5 billion for public entity clients since 2018 and has been instrumental in California wildfire litigation.

Mark Pifko: Shareholder focusing on high-profile class action cases. Pifko was co-lead trial counsel for the State of New Mexico in a trial against five retail pharmacies concerning their role in the opioid crisis, recovering a combined $274 million in settlements.

Dan Alberstone: Shareholder in the class action practice group. Alberstone served as co-lead counsel in a trial representing the State of Hawai’i against pharmaceutical companies, resulting in a $916 million award.

Leadership Changes

Specific recent leadership changes or appointments are not detailed in the available information.

Competitor Profile

Market Insights and Dynamics

The plaintiffs' law firm market is characterized by a competitive landscape with numerous firms specializing in various areas of litigation. Baron & Budd distinguishes itself through its extensive experience, successful track record, and commitment to public service.

Competitor Analysis

Key competitors include:

Weitz & Luxenberg: Specializes in asbestos and mesothelioma litigation.

Kazan, McClain, Satterley & Greenwood: Focuses on asbestos litigation.

Motley Rice: Engages in complex litigation, including securities fraud and environmental cases.

Baron & Budd's competitive advantages include its long-standing reputation, leadership in environmental litigation, and significant settlements in mass torts and class actions.

Strategic Collaborations and Partnerships

Baron & Budd collaborates with various organizations and entities to strengthen its market position and innovation capacity, including:

Public Entities: Representing cities, counties, and municipalities in litigation against opioid distributors and environmental contamination cases.

Legal Associations: Active participation in organizations such as the American Association for Justice (AAJ), contributing to public service initiatives.